Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 3/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703359 | 1.00 | MDM2 (0.40) | MDM2NR3C2GAAMAPTGFER | |
| SCHEMBL6703355 | 1.00 | MDM2 (0.40) | MDM2NR3C2GAAMAPTGFER | |
| SCHEMBL6703343 | 0.85 | FNTA (0.36) | SLC1A2FNTAFNTB | |
| SCHEMBL6703341 | 0.85 | FNTA (0.36) | SLC1A2FNTAFNTB | |
| SCHEMBL6703342 | 0.85 | FNTA (0.36) | SLC1A2FNTAFNTB | |
| SCHEMBL6702827 | 0.83 | MDM2 (0.35) | MDM2NR3C2GAAMAPTGFER | |
| SCHEMBL6703669 | 0.81 | PGR (0.38) | NR3C2GAAMAPTGFERAR | |
| SCHEMBL6703666 | 0.81 | PGR (0.38) | NR3C2GAAMAPTGFERAR | |
| SCHEMBL6703672 | 0.81 | PGR (0.38) | NR3C2GAAMAPTGFERAR | |
| SCHEMBL6481345 | 0.81 | FNTA (0.44) | MDM2GAAMAPTGFERPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220148-A1 | 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220148-A1 | 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | VCAM1, LTB4R, ITGB4 | MDM2 4529/4885NR3C2 813/4885GAA 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.